Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Member Advantages

Now Accepting Nominations for the 2025 Teaching Award! 
Is there an outstanding program director, professor, or urology educator who has made a difference to your urology training, or their training institution as a whole? If so, nominate them for the 2025 AUA Residents and Fellows Committee Teaching Award! The nomination deadline is December 15, 2024. Nominate Now
Applications are Now Open for the 2025 USMART Academy!
The Urology Scientific Mentoring and Research Training (USMART) Academy fosters creative and impactful mentorship between developing urology physician-scientists and established investigators with an exemplary track record of leadership and mentorship. Apply Now
Applications Now Open for the AUA Leadership Program!
Join the AUA Leadership Program—an exciting chance for urologists to enhance their leadership skills and influence the future of organized medicine! This dynamic year-long program selects top applicants from each AUA Section, offering a competitive platform for growth. Don’t miss your opportunity to be among the next generation of AUA leaders. Explore the program and apply today! Apply Today

Latest from Journals

JU | November 2024

Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial

Early PSA response has been found to be prognostic of outcomes in metastatic hormone sensitive prostate cancer. We performed a secondary analysis of the TITAN trial to determine if early PSA response was predictive of treatment efficacy in metastatic hormone sensitive prostate cancer patients.

View Now